Founded a decade ago, Kestra’s Wearable Cardioverter Defibrillator (WCD) has been used by more than 10,000 patients. The device provides autonomous detection and defibrillation for ventricular arrhythmias and is designed “specifically to meet the underserved needs of female cardiac patients,” according to the company.
Kestra Medical Technologies Lands $196M to Boost Commercialization of Wearable Defibrillator
Share: